Of potential importance for the design of clinical trials with TG/IL-2-expanded CIK cells, the frequency of bona fide Treg cells at any time-point in culture was similar when comparing PBMC preparations activated with IL-2 and TG or αCD3 mAb, thus reassuring against the infusion of excessive numbers of tumor-suppressive Treg cells [25]. Here, IL2 is linked to neoplasm.